Article
A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
Cancer - 1 Oct 2012
Reidy-Lagunes Diane L, Vakiani Efsevia, Segal Michal F, Hollywood Ellen M, Tang Laura H, Solit David B, Pietanza M Catherine, Capanu Marinela, Saltz Leonard B
Abstract excerpt
BACKGROUND: Neuroendocrine tumor (NET) cell lines frequently express both insulin-like growth factor (IGF) ligand and the cognate IGF-1 receptor (IGF-1R) and, as such, potentially depend on the activation of IGF-1R and its downstream effectors for growth and survival. Preclinical studies suggest that somatostatin analogs and mammalian target of rapamycin (mTOR) inhibitors exhibit antitumor activity against NETs...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.